Rhenium (186-Re) obisbemeda

A Phase 1 trial led by UT Health San Antonio demonstrated that Rhenium Obisbemeda more than doubled median survival time to 17 months in recurrent glioblastoma patients receiving high doses, compared to the typical 8-month survival.

Plus Therapeutics' Rhenium (186Re) Obisbemeda demonstrated a median overall survival of 17 months in patients receiving >100 Gy radiation dose, significantly outperforming the standard of care's 8-month survival rate.

Plus Therapeutics has secured FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda, targeting leptomeningeal metastases in lung cancer patients.

Plus Therapeutics secured $5.7 million in funding through a $3.7M private placement and $2.0M advance from CPRIT to support their Rhenium-186 radiotherapy development for leptomeningeal metastases.

Plus Therapeutics' ReSPECT-GBM Phase 1/2 trial update reveals Rhenium-186 Obisbemeda's favorable safety profile and potential efficacy in recurrent glioblastoma treatment.